ANVS
Annovis Bio Inc
1.20$
+1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
Annovis Bio Inc (ANVS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -22 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 12 | Q1 13 | Q2 13 | Q3 13 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.8 | 0.1 | 0.0 | -0.1 | -0.2 | -0.2 | -0.1 | -0.1 | -0.2 | -0.2 | 0.0 | -0.1 | -1.0 | -1.3 | -0.9 | -0.8 | -2.5 | -3.1 | -1.7 | -1.8 | -3.0 | -6.7 | -4.0 | -3.6 | -12 | -9.6 | -9.4 | -9.4 | -7.0 | -3.4 | -3.2 | -8.3 | -8.1 | -5.1 | -3.5 | -8.9 | -9.0 | -22 | -43 | |
| -0.1 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | 1.2 | 0.1 | – | 0.0 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | – | – | 0.0 | – | 1.1 | 0.6 | 0.1 | 0.0 | 0.0 | 0.8 | 3.9 | 3.4 | 1.9 | 2.4 | 1.5 | 1.5 | 1.6 | 0.6 | 0.9 | 0.4 | 1.6 | 0.4 | 1.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.2 | 1,791 | 1,792 | |
| 2.4 | 0.0 | 0.0 | 0.0 | – | – | – | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 1.1 | 0.6 | 0.1 | 0.0 | 0.0 | 0.8 | 3.9 | 3.4 | 1.9 | 2.4 | 0.6 | 1.5 | 1.6 | 0.6 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.2 | 0.1 | -0.6 | -0.1 | -0.5 | 0.8 | 0.7 | -0.6 | 0.3 | 0.3 | -1.2 | -2.7 | 0.1 | -2.0 | -3.4 | -1.6 | 4.7 | 0.1 | 0.4 | 2.8 | 0.7 | -3.2 | -2.5 | 0.5 | 3.4 | 0.3 | 8.7 | -7.7 | 4.6 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.3 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | – | – | – | – | – | – | – | – | – | 12 | 0.0 | – | – | 0.0 | 47 | 0.0 | – | – | – | – | – | 0.0 | 8.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | – | – | – | – | – | – | 0.5 | 0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | – | – | – | 0.2 | 0.0 | – | 0.5 | 0.5 | -0.1 | 0.0 | 0.0 | 12 | 0.0 | 12 | 12,032 | 0.0 | 47 | 0.0 | 46,697 | 0.0 | 0.0 | 0.0 | 4.6 | 0.0 | 8.6 | 0.0 | 8.8 | 4.4 | 4.2 | 12 | 6.2 | 20 | 0.0 | 1.6 | 13 | 3.7 | 26 | 45 | |
| -1.0 | 0.1 | 0.0 | -0.1 | 0.1 | -0.2 | -0.1 | -0.1 | 0.3 | -0.2 | 0.0 | -0.1 | 11 | -1.4 | -0.9 | -0.8 | -2.5 | 44 | -1.8 | -1.8 | -3.0 | -6.7 | -4.0 | -3.6 | -12 | -1.0 | -9.4 | -0.6 | -2.6 | 0.9 | 8.6 | -2.1 | 12 | -5.1 | -1.8 | 4.2 | -5.3 | 4.5 | 1.6 | |
| – | – | – | – | -0.2 | -0.2 | -0.1 | -0.1 | -0.2 | -0.2 | 0.0 | -0.1 | -1.0 | -1.3 | -0.9 | -0.8 | -2.5 | -3.1 | -1.7 | -1.8 | -3.0 | -6.7 | -4.0 | -3.6 | -12 | -9.6 | -9.4 | -9.4 | -7.0 | -3.4 | -3.2 | -8.3 | -8.1 | -5.1 | -3.5 | -8.9 | -9.0 | -22 | -43 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.